Docoh
Loading...

35 results

Filter options loading...
Top filers
Top filing types
Recent filing years
DEF 14A
PCSA Processa Pharmaceuticals Inc
22 Apr 21
Definitive proxy
2:00pm
financial expert” within the meaning of the SEC regulations and the applicable Nasdaq Listing Rules. The audit committee met four times during 2020 … in building an expert regulatory group to address both commercial and development needs for complex products such as Acthar. Dr. Bigora’s role at Questcor
10-K/A
2020 FY
PCSA Processa Pharmaceuticals Inc
7 Apr 21
Annual report (amended)
4:23pm
and drug delivery systems in animals and humans. Dr. Young is an expert in small molecule and protein non-clinical and clinical drug development. He … , she assisted in building an expert regulatory group to address both commercial and development needs for complex products such as Acthar. Dr. Bigora’s
S-3
EX-5.1
PCSA Processa Pharmaceuticals Inc
1 Apr 21
Shelf registration
8:00pm
of the Registration Statement. In giving this consent, we do not thereby admit that we are an “expert” within the meaning of the Act or that we
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
is an expert in small molecule and protein non-clinical and clinical drug development. He has served on FDA Advisory Committees, was Co-Principal … , events of material importance to Questcor’s subsequent success. During her time at Questcor, she assisted in building an expert regulatory group
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
the biological properties of drugs and drug delivery systems in animals and humans. Dr. Young is an expert in small molecule and protein non-clinical and clinical … . During her time at Questcor, she assisted in building an expert regulatory group to address both commercial and development needs for complex products
S-1/A
ja7wbg44i1l4fw oa
30 Sep 20
IPO registration (amended)
4:06pm
S-1/A
i3kvi
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
g4m8p7csng5teh7t6e
17 Jul 20
IPO registration (amended)
5:25pm
10-K
aymw4bk7naab6qsxmskc
5 Mar 20
Annual report
7:00pm
S-1
veb9zgu010c r6t3qm5u
13 Dec 19
IPO registration
5:32pm
DEF 14A
7j8gup 6iqw4oiegofx
26 Apr 19
Definitive proxy
5:02pm
10-K/A
781guckqkmq6
5 Apr 19
Annual report (amended)
9:40pm
10-K
ctxqb5t2ot zei
28 Mar 19
Annual report
5:25pm
424B3
4o8edotik5k3
9 Nov 18
Prospectus supplement
5:04pm
S-1/A
pgx6ue wve
30 Oct 18
IPO registration (amended)
4:19pm
S-1/A
sigxwi9
9 Oct 18
IPO registration (amended)
5:32pm
S-1/A
EX-5.1
au1a7n tc
9 Oct 18
IPO registration (amended)
5:32pm
S-1/A
oymhaz4xf67pa
13 Sep 18
IPO registration (amended)
8:00pm
S-1
rgv9 h7sqx
29 Jul 18
IPO registration
8:00pm
S-1
EX-5.1
gkori zxhg
29 Jul 18
IPO registration
8:00pm